EGFR and non-small cell lung carcinoma: In NSCLC patients, EGFR tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and icotinib prolonged PFS significantly compared with chemotherapy (Pan et al., 2014; Batson et al., 2017).